You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)子公司治療乳腺癌新藥獲美國FDA快速通道審評認證
阿思達克 06-17 10:14

復星醫藥(02196.HK)(600196.SH)公布,旗下控股子公司復星弘創(蘇州)醫藥科技收到美國食品藥品監督管理局(FDA)關於新藥ORIN1001用於治療復發性、難治性、轉移性乳腺癌(包括三陰乳腺癌)獲得快速通道審評認證的函。

該新藥為集團自主研發的具有新(酉每)型靶點、新作用機制和新化學結構類型的首創小分子藥物,用於治療晚期實體瘤,其第一個探索中的適應症為複發性、難治性、轉移性乳腺癌。截至昨日(16日),在全球範圍內尚無與該新藥同類型產品上市。

截至今年5月,集團現階段針對該新藥已累計研發投入約4,547萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account